Literature DB >> 31526843

Summary of the Third Annual Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling.

Sarah A Holstein1, Zaid Al-Kadhimi2, Luciano J Costa3, Theresa Hahn4, Parameswaran Hari5, Jens Hillengass4, Allison Jacob6, Nikhil C Munshi7, Stefania Oliva8, Marcelo C Pasquini5, Qian Shi9, Edward A Stadtmauer10, Stephanie L Waldvogel11, Philip L McCarthy4.   

Abstract

The third annual Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling was held on November 29, 2018, at the American Society of Hematology (ASH) annual meeting. This workshop featured the latest research focused on minimal residual disease (MRD) assessment and immune profiling (IP) in myeloma as well as discussion of the statistical and regulatory issues intrinsic to the development of MRD as a surrogate endpoint. In this report, we provide a summary of the workshop and focus on the integration of MRD and IP assessment into trial design and clinical practice.
Copyright © 2019 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CAR T cell; Endpoint; Immune profiling; Minimal residual disease; Multiple myeloma

Mesh：

Year:  2019        PMID： 31526843      PMCID： PMC6942175          DOI： 10.1016/j.bbmt.2019.09.015

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN： 1083-8791            Impact factor:   5.742


  58 in total

1.  Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma.

Authors:  Noopur Raje; Jesus Berdeja; Yi Lin; David Siegel; Sundar Jagannath; Deepu Madduri; Michaela Liedtke; Jacalyn Rosenblatt; Marcela V Maus; Ashley Turka; Lyh-Ping Lam; Richard A Morgan; Kevin Friedman; Monica Massaro; Julie Wang; Greg Russotti; Zhihong Yang; Timothy Campbell; Kristen Hege; Fabio Petrocca; M Travis Quigley; Nikhil Munshi; James N Kochenderfer
Journal:  N Engl J Med       Date:  2019-05-02       Impact factor: 91.245

2.  The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myeloma.

Authors:  Sharmilan Thanendrarajan; Erming Tian; Pingping Qu; Pankaj Mathur; Carolina Schinke; Frits van Rhee; Maurizio Zangari; Leo Rasche; Niels Weinhold; Daisy Alapat; William Bellamy; Cody Ashby; Sandra Mattox; Joshua Epstein; Shmuel Yaccoby; Bart Barlogie; Antje Hoering; Michael Bauer; Brian A Walker; Faith E Davies; Gareth J Morgan
Journal:  Haematologica       Date:  2017-05-26       Impact factor: 9.941

3.  The Future of Chimeric Antigen Receptor T Cell Therapy for the Treatment of Multiple Myeloma.

Authors:  R Frank Cornell; Luciano J Costa
Journal:  Biol Blood Marrow Transplant       Date:  2018-11-16       Impact factor: 5.742

4.  Immature monocytes from G-CSF-mobilized peripheral blood stem cell collections carry surface-bound IL-10 and have the potential to modulate alloreactivity.

Authors:  A R Fraser; G Cook; I M Franklin; J G Templeton; M Campbell; T L Holyoake; J D M Campbell
Journal:  J Leukoc Biol       Date:  2006-08-08       Impact factor: 4.962

5.  T Cell Transcriptional Profiling and Immunophenotyping Uncover LAG3 as a Potential Significant Target of Immune Modulation in Multiple Myeloma.

Authors:  Fabienne Lucas; Michael Pennell; Ying Huang; Don M Benson; Yvonne A Efebera; Maria Chaudhry; Tiffany Hughes; Jennifer A Woyach; John C Byrd; Suohui Zhang; Desiree Jones; Xiangnan Guan; Christin E Burd; Ashley E Rosko
Journal:  Biol Blood Marrow Transplant       Date:  2019-08-21       Impact factor: 5.742

6.  Individual patient data analysis of progression-free survival versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials: findings from the analysis and research in cancers of the digestive system database.

Authors:  Qian Shi; Aimery de Gramont; Axel Grothey; John Zalcberg; Benoist Chibaudel; Hans-Joachim Schmoll; Matthew T Seymour; Richard Adams; Leonard Saltz; Richard M Goldberg; Cornelis J A Punt; Jean-Yves Douillard; Paulo M Hoff; Joel Randolph Hecht; Herbert Hurwitz; Eduardo Díaz-Rubio; Rainer Porschen; Niall C Tebbutt; Charles Fuchs; John Souglakos; Alfredo Falcone; Christophe Tournigand; Fairooz F Kabbinavar; Volker Heinemann; Eric Van Cutsem; Carsten Bokemeyer; Marc Buyse; Daniel J Sargent
Journal:  J Clin Oncol       Date:  2014-11-10       Impact factor: 44.544

7.  Immunologic attributes of cytokine mobilized peripheral blood stem cells and recovery following transplantation.

Authors:  J E Talmadge; E C Reed; A Kessinger; C A Kuszynski; G A Perry; C L Gordy; K C Mills; M L Thomas; S J Pirruccello; B A Letheby; M A Arneson; J D Jackson
Journal:  Bone Marrow Transplant       Date:  1996-01       Impact factor: 5.483

8.  Gastrointestinal Microbiome and Mycobiome Changes during Autologous Transplantation for Multiple Myeloma: Results of a Prospective Pilot Study.

Authors:  Najla El Jurdi; Ali Filali-Mouhim; Iman Salem; Mauricio Retuerto; Nina Margaret Dambrosio; Linda Baer; Hillard M Lazarus; Paolo Caimi; Brenda Cooper; Benjamin Tomlinson; Leland Metheny; Ehsan Malek; Folashade Otegbeye; Rafick-Pierre Sekaly; Mahmoud Ghannoum; Marcos de Lima
Journal:  Biol Blood Marrow Transplant       Date:  2019-04-05       Impact factor: 5.742

9.  Peripheral Immunotype Correlates with Minimal Residual Disease Status and Is Modulated by Immunomodulatory Drugs in Multiple Myeloma.

Authors:  Manisha Bhutani; David Foureau; Qing Zhang; Myra Robinson; Adina S Wynn; Nury M Steuerwald; Lawrence J Druhan; Fei Guo; Katherine Rigby; Mitchell Turner; Daniel Slaughter; Reed Friend; Shebli Atrash; James T Symanowski; Belinda R Avalos; Edward A Copelan; Peter M Voorhees; Saad Z Usmani
Journal:  Biol Blood Marrow Transplant       Date:  2018-11-24       Impact factor: 5.742

10.  Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial.

Authors:  Sarah A Holstein; Sin-Ho Jung; Paul G Richardson; Craig C Hofmeister; David D Hurd; Hani Hassoun; Sergio Giralt; Edward A Stadtmauer; Daniel J Weisdorf; Ravi Vij; Jan S Moreb; Natalie S Callander; Koen van Besien; Teresa G Gentile; Luis Isola; Richard T Maziarz; Asad Bashey; Heather Landau; Thomas Martin; Muzaffar H Qazilbash; Cesar Rodriguez; Brian McClune; Robert L Schlossman; Scott E Smith; Vera Hars; Kouros Owzar; Chen Jiang; Molly Boyd; Chelsea Schultz; Marcia Wilson; Parameswaran Hari; Marcelo C Pasquini; Mary M Horowitz; Thomas C Shea; Steven M Devine; Charles Linker; Kenneth C Anderson; Philip L McCarthy
Journal:  Lancet Haematol       Date:  2017-08-17       Impact factor: 18.959
View more
  7 in total

1.  Long-Term Follow-up of CALGB (Alliance) 100001: Autologous Followed by Nonmyeloablative Allogeneic Transplant for Multiple Myeloma.

Authors:  Sarah A Holstein; Vera J Suman; Kouros Owzar; Katelyn Santo; Don M Benson; Thomas C Shea; Thomas Martin; Margarida Silverman; Luis Isola; Ravi Vij; Bruce D Cheson; Charles Linker; Kenneth C Anderson; Paul G Richardson; Philip L McCarthy
Journal:  Biol Blood Marrow Transplant       Date:  2020-04-20       Impact factor: 5.742

Review 2.  MRD Assessment in Multiple Myeloma: Progress and Challenges.

Authors:  Luca Bertamini; Mattia D'Agostino; Francesca Gay
Journal:  Curr Hematol Malig Rep       Date:  2021-05-05       Impact factor: 3.952

3.  Minimal residual disease in multiple myeloma: why, when, where.

Authors:  Andrew J Yee; Noopur Raje
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

4.  Proceedings from the Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Immune and Cellular Therapy in Multiple Myeloma.

Authors:  Sarah A Holstein; Fotis Asimakopoulos; Abdel Kareem Azab; Giada Bianchi; Manisha Bhutani; Leslie A Crews; Tom Cupedo; Hannah Giles; Sarah Gooding; Jens Hillengass; Lukas John; Shari Kaiser; Lydia Lee; Kylee Maclachlan; Marcelo C Pasquini; Flavia Pichiorri; Nina Shah; Monica Shokeen; Brian R Shy; Eric L Smith; Raluca Verona; Saad Z Usmani; Philip L McCarthy
Journal:  Transplant Cell Ther       Date:  2022-05-21

Review 5.  Summary of the 2019 Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling.

Authors:  Sarah A Holstein; Alan Howard; David Avigan; Manisha Bhutani; Adam D Cohen; Luciano J Costa; Madhav V Dhodapkar; Francesca Gay; Nicole Gormley; Damian J Green; Jens Hillengass; Neha Korde; Zihai Li; Sham Mailankody; Paola Neri; Samir Parekh; Marcelo C Pasquini; Noemi Puig; G David Roodman; Mehmet Kemal Samur; Nina Shah; Urvi A Shah; Qian Shi; Andrew Spencer; Vera J Suman; Saad Z Usmani; Philip L McCarthy
Journal:  Biol Blood Marrow Transplant       Date:  2020-06-24       Impact factor: 5.742

Review 6.  The 2020 BMT CTN Myeloma Intergroup Workshop on Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma.

Authors:  Sarah A Holstein; Nizar Bahlis; P Leif Bergsagel; Manisha Bhutani; Niccolo Bolli; Carrie Brownstein; Pierre Demolis; David Foureau; Francesca Gay; Irene M Ghobrial; Nicole Gormley; Jens Hillengass; Martin Kaiser; Marcela V Maus; J Joseph Melenhorst; Maximilian Merz; Michael O Dwyer; Bruno Paiva; Marcelo C Pasquini; Nina Shah; Sandy W Wong; Saad Z Usmani; Philip L McCarthy
Journal:  Transplant Cell Ther       Date:  2021-06-06

Review 7.  Predictive Role of Immune Profiling for Survival of Multiple Myeloma Patients.

Authors:  Liu Zhaoyun; Fu Rong
Journal:  Front Immunol       Date:  2021-07-05       Impact factor: 7.561
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.